Phio Pharmaceuticals holds 2026 annual meeting, expands incentive plan
Shareholders approved a 1,500,000-share increase to Phio's long-term incentive plan and elected six directors at the September 28, 2026 meeting.
Phio Pharmaceuticals Corp. held its 2026 Annual Meeting of Stockholders via live webcast on September 28, 2026.1
At the meeting, stockholders approved an amendment to the amended and restated 2020 Phio Pharmaceuticals Corp. Long Term Incentive Plan, which increased the number of shares available for issuance under the plan by 1,500,000, to a total of 2,452,017 shares.1
Stockholders also elected each of six directors to serve until the Company's 2027 Annual Meeting of Stockholders and ratified the appointment of Grant Thornton, LLP as the company's outside auditor for fiscal year 2026.1
The company reported 11,617,250 shares of common stock outstanding as of the August 4, 2026 record date, with 5,207,580 shares present in person or by proxy at the meeting.1
In the director election, vote totals varied among nominees. Jonathan E. Freeman, Ph.D. received 1,296,890 votes for and 87,593 withheld1, while R. Todd Plott, M.D. received 1,347,034 votes for and 37,449 withheld1, the highest support among the nominees.
On the auditor ratification, shareholders cast 5,087,608 votes for, 88,779 against, and 31,193 abstentions1.
The plan amendment itself passed with 1,155,945 votes for, 194,070 against, and 34,468 abstentions1, alongside 3,823,097 broker non-votes.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.